DWTX: Financing Secures Funding Through Phase 2b Data Readout [Yahoo! Finance]
Dogwood Therapeutics, Inc. (DWTX)
Company Research
Source: Yahoo! Finance
On January 15, 2026, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced a securities purchase agreement with a single healthcare-focused institutional investor for up to approximately $12.5 million in gross proceeds through a registered direct offering and a concurrent private placement. An aggregate of 4,386,037 shares of common stock were sold together with one warrant to purchase one share of common stock at a combined purchase price of $2.85. The warrants have an exercise price of $3.28 and are exercisable for five and one-half years following the effective date of shareholder approval. In addition to the upfront gross proceeds of $12.5 million, an additional $14.4 million in gross proceeds is possible upon the exercise of the warrants. Following this financing, we estimate that the company now has sufficient funding past the anticipated data readout for the Phase 2b HALT-CINP trial of Halneuron® in patients with moderate-to-severe chemotherapy-induced neuropathic pain (CINP).
Show less
Read more
Impact Snapshot
Event Time:
DWTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DWTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DWTX alerts
High impacting Dogwood Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DWTX
News
- Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026 [Yahoo! Finance]Yahoo! Finance
- Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026GlobeNewswire
- Dogwood Therapeutics (NASDAQ:DWTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.MarketBeat
- Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b DevelopmentGlobeNewswire
- Dogwood Therapeutics Says Interim Phase 2B Data Show Pain Improvement With Halneuron [Yahoo! Finance]Yahoo! Finance
DWTX
Earnings
- 11/6/25 - Miss
DWTX
Analyst Actions
- 1/30/26 - HC Wainwright
DWTX
Sec Filings
- 1/30/26 - Form EFFECT
- 1/23/26 - Form PRE
- 1/20/26 - Form 8-K
- DWTX's page on the SEC website